DrugPatentWatch Database Preview
Ramipril - Generic Drug Details
» See Plans and Pricing
What are the generic drug sources for ramipril and what is the scope of patent protection?
Ramipril
is the generic ingredient in two branded drugs marketed by King Pharms Llc, Accord Hlthcare, Actavis Elizabeth, Apotex, Aurobindo Pharma Ltd, Chartwell Molecular, Cipla, Dr Reddys Labs Ltd, Hikma, Lupin, Ranbaxy Labs Ltd, Teva Pharms, Watson Labs, Yaopharma Co Ltd, Zydus Pharms Usa, King Pfizer, Mylan Pharms Inc, and Zydus Pharms Usa Inc, and is included in nineteen NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.Ramipril has forty-seven patent family members in thirty-two countries.
There are nineteen drug master file entries for ramipril. Twenty-two suppliers are listed for this compound.
Summary for ramipril
International Patents: | 47 |
US Patents: | 1 |
Tradenames: | 2 |
Applicants: | 18 |
NDAs: | 19 |
Drug Master File Entries: | 19 |
Suppliers / Packagers: | 22 |
Bulk Api Vendors: | 83 |
Clinical Trials: | 145 |
Patent Applications: | 6,940 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price trends for ramipril |
Drug Sales Revenues: | Drug sales revenues for ramipril |
What excipients (inactive ingredients) are in ramipril? | ramipril excipients list |
DailyMed Link: | ramipril at DailyMed |
Recent Clinical Trials for ramipril
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Bari | Phase 4 |
Fondazione Schena | Phase 4 |
University of California, San Diego | Phase 2 |
Pharmacology for ramipril
Drug Class | Angiotensin Converting Enzyme Inhibitor |
Mechanism of Action | Angiotensin-converting Enzyme Inhibitors |
Medical Subject Heading (MeSH) Categories for ramipril
US Patents and Regulatory Information for ramipril
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aurobindo Pharma Ltd | RAMIPRIL | ramipril | CAPSULE;ORAL | 091604-002 | Jun 8, 2011 | AB | RX | No | No | Start Trial | Start Trial | Start Trial | |||
Cipla | RAMIPRIL | ramipril | CAPSULE;ORAL | 077004-004 | Aug 7, 2008 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
Dr Reddys Labs Ltd | RAMIPRIL | ramipril | CAPSULE;ORAL | 078191-004 | Jun 18, 2008 | AB | RX | No | No | Start Trial | Start Trial | Start Trial | |||
Aurobindo Pharma Ltd | RAMIPRIL | ramipril | CAPSULE;ORAL | 091604-001 | Jun 8, 2011 | AB | RX | No | No | Start Trial | Start Trial | Start Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ramipril
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
King Pfizer | ALTACE | ramipril | TABLET;ORAL | 022021-003 | Feb 27, 2007 | Start Trial | Start Trial |
King Pfizer | ALTACE | ramipril | TABLET;ORAL | 022021-001 | Feb 27, 2007 | Start Trial | Start Trial |
King Pharms Llc | ALTACE | ramipril | CAPSULE;ORAL | 019901-004 | Jan 28, 1991 | Start Trial | Start Trial |
King Pharms Llc | ALTACE | ramipril | CAPSULE;ORAL | 019901-002 | Jan 28, 1991 | Start Trial | Start Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ramipril
Country | Patent Number | Estimated Expiration |
---|---|---|
Germany | 60022525 | Start Trial |
Hong Kong | 1048267 | Start Trial |
Israel | 148127 | Start Trial |
Czech Republic | 300687 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ramipril
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0265685 | C980030 | Netherlands | Start Trial | PRODUCT NAME: FELODIPINE, DESGEWENST IN DE VORM VAN FYSIOLOGISCH AANVAARDBAAR ZOUT, EN (2S, 3AS, 6AS)-1-[(S)-N-[(S)-1-CARBOXY-3-FENYLPROPYL]A LANYL]OCTAHYDROCYCLOPENTA[B]-PYRROOL-2-CARBONZUUR (RAMIPRILAAT) , DESGEWENST IN DE VORM VAN EEN .....ZIE VERDER IN HET DOSSIER; NAT. REGISTRATION NO/ DATE: RVG 22449, RVG 22450 19980618; FIRST REGISTRATION: SE 13596, 13597 19970919 |
0265685 | 99C0001 | Belgium | Start Trial | PRODUCT NAME: FELODIPINUM + RAMIPRILUM; NATL. REGISTRATION NO/DATE: 354 IS 373 F 3 19981103; FIRST REGISTRATION: SE 13597 19970919 |
0265685 | SPC/GB98/047 | United Kingdom | Start Trial | PRODUCT NAME: COMBINATIONS OF RAMIPRIL, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, AND FELODIPINE, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: SE 13596 19970919; SE 13597 19970919; UK 00017/0402 19980825; UK 00017/0403 19980825 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:






Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.